MacroGenics presents MGC026 data showing 27.3% best overall response rate in head and neck cancer
MGNX•MacroGenics presented data showing a 27.3% best overall response rate among 22 heavily pretreated head-and-neck cancer patients treated with MGC026. Confirmed responses were 18.2%, disease control was 63.6%, and the company reported $327 million in pro forma cash and securities, with runway projected through 2028.
1. Cancer study results
MacroGenics presented MGC026 data at ESMO, reporting a 27.3% best overall response rate among 22 heavily pretreated head-and-neck cancer patients. Confirmed responses reached 18.2%, and the disease control rate was 63.6%.
2. Safety and next steps
No treatment-related discontinuations occurred in the 27-patient expansion cohort, and no interstitial lung disease, pneumonitis or ocular toxicity was reported. A front-line MGC026-pembrolizumab combination study is planned for early 2027, with the next MGC026 update anticipated in mid-2027.
3. Cash runway
Pro forma cash equivalents and marketable securities totaled $327 million, supporting a projected cash runway through 2028.
